Biotech Stock 685% Draws Big Investment Amid FDA Filings
A biotech stock that sprinted 685% in months drew a sizeable institutional bet as it pressed ahead with two FDA filin...
We evaluate long-term return potential across index funds to help you identify candidates with the strongest growth prospects.
28,522 articlesA biotech stock that sprinted 685% in months drew a sizeable institutional bet as it pressed ahead with two FDA filin...
As July 22 approaches, investors face a familiar crossroads: take a position before earnings or wait for the full pic...
An accessible analysis of what this $405,000 bj's insider sale means for investors, plus practical steps to read insi...
When a high-profile NFL deal blows up in public, it isn’t just about football. It’s a masterclass in money, risk, and...
A DRAM-focused memory ETF delivered triple-digit gains in 2026, outperforming many AI names as investors weighed AI i...
Clorox has stacked a long streak of dividend increases, but reaching 50 years could hinge on a crucial strategic shif...
As investors prepare for Personalis (PSNL) 2025 earnings, this guide breaks down what to watch, how to interpret the ...
Tesla's robotaxi venture is facing real-world hurdles in Texas. This article breaks down what those problems mean for...
When a CEO sells a large block of stock, investors take notice. This article breaks down what nLIGHT's sold nearly 25...
A biotech stock surged 75% last quarter and drew a new $9 million investment, signaling confidence from sophisticated...
NVIDIA and BroadCOM present two paths for AI exposure: explosive growth versus steady income. The choice hinges on go...
In this analysis, we unpack what Andy Jassy's recent remarks mean for Amazon stock and AWS growth. Learn actionable s...